Generic Erosion of Market Leading Therapies Will Constrain Growth in the Parkinson's Disease Drug Market Over the Next Decade
Posted on: Tuesday, 17 June 2008, 09:00 CDT
WALTHAM, Mass., June 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the generic erosion of market leading therapies will constrain the Parkinson's disease drug market, resulting in an annual market growth rate of only 1.4 percent through 2017 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
The new Pharmacor report entitled Parkinson's Disease finds that the generic erosion of Boehringer Ingelheim's Mirapex/Mirapexin/Sifrol, GlaxoSmithKline's Requip, Teva/Lundbeck's Agilect/Azilect and Novartis/Orion's Stalevo will cause sales of these agents to decline over the next decade, despite their increased use. The key agents in the dopamine agonist drug class, Requip and Mirapex/Mirapexin/Sifrol, will be most significantly affected by near-term generic erosion through 2012.
The modest growth of the Parkinson's disease drug market over the next decade will be driven by the arrival of once-daily formulations of current market leading dopamine agonists, GlaxoSmithKline/SkyePharma's Requip XL/CR/LP and Boehringer Ingelheim's pramipexole ER. Growth will also be driven by the launch of two new therapies-Merck Serono/Newron's safinamide and Solvay's pardoprunox-and by increases in drug-treatment rates due to aging populations in the world's major pharmaceutical markets.
"The greatest unmet need in Parkinson's disease treatment, the need for a disease-modifying therapy, will remain unfulfilled over the next 10 years," said Sami Fam, Ph.D., analyst at Decision Resources. "Key opinion leaders in this therapeutic area unanimously agree that the most critical need is for drugs that can act on the pathological mechanisms of Parkinson's disease and provide neuroprotection and/or neurorestoration. Critical to addressing this unmet need will be a better understanding of the cellular mechanisms that underlie the pathology of Parkinson's disease."
About Decision Resources
Decision Resources (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 emarshall@dresources.com
Decision Resources
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,+1-781-296-2563, emarshall@dresources.com
Web site: http://www.decisionresources.com/
Source: PRNewswire
Related Articles
- Diabetes Drugs Emerge As Top Force in Drug Spending Growth
- AVANIR Receives FDA Approval for New Formulation of Currently Marketed Antipsychotic Drug FazaClo
- Pro-Pharmaceuticals Collaborates With Chemwerth to Scale-Up Production of DAVANAT(R) for Initial Marketing Needs
- Avanir Receives FDA Approvable Letter for New Formulation of Currently Marketed Antipsychotic Drug FazaClo
- Levodopa Remains the Best at Treating Parkinson's Disease As There Are Few Drugs That Match Its Success
- '2006 US Market Advanced Drug Delivery Systems Probing the Route to Growth' Provides Readers With Information and Analysis About Key Developments Driving the Industry in the Middle of 2005
- FDA Delays Decision on Celgene Blood Drug
- Research and Markets: Cardiovascular Drugs- Clinical Trial Design and Expanding Medical Device Market Analysed
- Crohn's Disease Drug Market to Experience Dynamic Growth of 73% By 2013
- Local PC market all set for growth, NEW STRAITS TIMES-MANAGEMENT
 |
 |
User Comments (0)
RSS Feeds